Lynkuet (Elinzanetant): The 2025 FDA-Approved Hot Flash Drug

If you have been counting down the minutes to your next hot flash, waking up soaked through your sheets, or simply feeling like your body turned against you overnight, you are not alone. Vasomotor symptoms affect roughly three out of four women during the menopause transition, and for many of us, they are not a mild inconvenience. They are life-disrupting. The good news is that 2025 brought a genuinely new kind of relief: the FDA approved Lynkuet (elinzanetant), the first drug of its class to reach American pharmacies. It does not contain hormones, it does not mimic them, and it works through a completely different pathway than anything that came before it.

What Is Elinzanetant and Why Is It Different?

Elinzanetant (brand name Lynkuet, made by Bayer) received FDA approval on October 24, 2025, for the treatment of moderate to severe vasomotor symptoms due to menopause. It belongs to an entirely new pharmacological class called dual neurokinin-1 and neurokinin-3 (NK1/NK3) receptor antagonists. No other approved drug in the United States works on both of these receptors simultaneously, which is why the FDA recognized it as the first and only dual neurokinin antagonist for this indication.

To understand why that matters, it helps to take a quick trip into the brain. Deep in the hypothalamus, a cluster of neurons called KNDy neurons (named for the three signaling molecules they produce: kisspeptin, neurokinin B, and dynorphin) act as the brain's thermostat. When estrogen levels are stable, these neurons are calm and your body temperature stays relatively steady. When estrogen drops during perimenopause and menopause, those KNDy neurons become hyperactive. They flood the system with excess neurokinin B, which triggers the brain's heat-dissipation response: blood vessels dilate, you flush, you sweat, and your core body temperature fluctuates. That is a hot flash at the neurological level.

Elinzanetant works by blocking both the NK3 receptor (which directly triggers that temperature dysregulation) and the NK1 receptor (which is involved in sleep regulation and peripheral blood vessel dilation). The result, as shown across multiple large clinical trials, is a meaningful reduction in both the frequency and severity of hot flashes, along with better sleep. Importantly, it does all of this without touching your hormones. It does not add estrogen, mimic estrogen, or interfere with the hormonal environment of your body.

What the Clinical Trials Actually Showed

The FDA approval of Lynkuet was built on results from the OASIS clinical program, a series of rigorous Phase 3 randomized, double-blind, placebo-controlled studies. Across OASIS 1, 2, and 3, researchers enrolled more than 1,300 women experiencing moderate to severe vasomotor symptoms. The findings were consistent and compelling:

Hot flash frequency dropped significantly. Women taking elinzanetant saw statistically significant reductions in how often they experienced moderate to severe hot flashes compared to those on placebo, with improvements measurable as early as week 1. In the OASIS 3 trial, participants saw more than a 73% reduction in vasomotor symptom frequency and severity by week 12.

Sleep improved, too, and not just because of fewer night sweats. Across the four OASIS trials (including the NIRVANA study), elinzanetant reduced sleep disturbance scores by an average of 4.92 points compared to placebo. Researchers noted that more than half of the sleep benefit appeared to occur independently of vasomotor symptom relief, likely because of the drug's action on NK1 receptors, which directly regulate sleep architecture. This dual benefit was highlighted at The Menopause Society's 2025 Annual Meeting, where Bayer-sponsored data from nearly 700 US women confirmed the drug's strong one-year safety profile and consistent efficacy.

Results came fast. Unlike some treatments that require weeks before you notice a difference, women in the OASIS trials reported meaningful symptom relief within the first week. That early onset matters enormously when you are in the thick of menopause and every night feels like an endurance test.

Who Is Lynkuet Designed For?

Lynkuet is approved for women experiencing moderate to severe vasomotor symptoms due to menopause. In practical terms, "moderate to severe" means hot flashes that disrupt your daily activities, interrupt your sleep, or occur frequently enough to affect your quality of life. If that description resonates, this drug was evaluated with you in mind.

Because it contains no hormones, elinzanetant opens a meaningful door for women who have been told they cannot use traditional hormone therapy. The FDA specifically noted its non-hormonal mechanism as a key reason it expands the treatment landscape. This includes:

• Women who prefer not to use hormones for personal or philosophical reasons
• Women with a history of hormone-sensitive conditions who have been advised to avoid estrogen
• Women who tried hormone therapy and did not tolerate it well
• Women who are not yet in full menopause and want a non-hormonal bridge during perimenopause

Particularly exciting is the emerging data on women with breast cancer. A study published in 2025 in the New England Journal of Medicine examined elinzanetant in women with hormone receptor-positive breast cancer who were taking tamoxifen or an aromatase inhibitor (endocrine therapy). These women typically suffer some of the worst hot flashes imaginable, caused by both menopause and their cancer treatment, and have historically had very limited options for relief. In the OASIS 4 trial, which enrolled 474 women on endocrine therapy who were experiencing approximately 11 moderate to severe hot flashes per day, those taking elinzanetant had six fewer daily hot flashes after just four weeks, and eight fewer per day by week 12. The International Menopause Society has since noted elinzanetant's potential as a safe option in this population, though women with breast cancer should always discuss any new medication with their oncology team before starting.

There are also women for whom Lynkuet is not appropriate. It is contraindicated during pregnancy. It should not be started if your liver enzyme levels (ALT or AST) are already elevated at two times the upper limit of normal or higher. Your provider will likely check a baseline liver panel before you begin.

How You Take It

Lynkuet comes as a capsule and the standard dose is 120 mg (two capsules) taken once daily at bedtime. The bedtime timing is intentional: it aligns peak drug levels with the overnight hours when hot flashes and night sweats tend to be most disruptive, and it means any mild drowsiness that some users experience happens while you are already winding down for sleep.

If you take certain medications that interact with elinzanetant, your provider may prescribe the lower 60 mg (one capsule) dose instead. This is an important conversation to have, because elinzanetant does interact with some common drugs metabolized by the liver's CYP3A4 enzyme. Bring a complete medication list to your appointment. Our appointment prep tool can help you organize that conversation before you walk in the door.

Side Effects and What to Watch For

In clinical trials, elinzanetant was generally well tolerated. The most commonly reported side effects were mild to moderate and included:

• Headache
• Fatigue
• Dizziness or drowsiness (particularly in the first days of use)
• Nausea or stomach discomfort
• Gastroesophageal reflux (heartburn)

The FDA label also carries warnings about two less common but more serious concerns. First, a small number of patients experienced elevated liver enzymes. This is reversible when the medication is stopped, but your provider will want to monitor your liver function periodically while you are on Lynkuet. Second, there is a warning about CNS depressive effects (dizziness, drowsiness) that could theoretically impair daytime function if the medication's effects extend past bedtime. For most women in the trials, this was not a problem at the standard bedtime dosing schedule, but it is worth discussing if you notice lingering grogginess.

A very small percentage of patients (about 0.5%) experienced mild to moderate photosensitivity (sensitivity to sunlight). In most cases this resolved on its own even without stopping the medication.

Compared to other non-hormonal treatment options, elinzanetant's side effect profile is considered favorable. There are no cardiovascular warnings, no impact on bone density, and no hormonal effects of any kind.

How Does Elinzanetant Compare to Fezolinetant (Veozah)?

If you have been following menopause news closely, you may know that another non-hormonal drug called fezolinetant (Veozah) was FDA-approved back in May 2023. Both drugs work on the KNDy neuron pathway. The key difference is that fezolinetant targets only the NK3 receptor, while elinzanetant targets both NK3 and NK1. In a matching-adjusted indirect comparison published in the journal Maturitas, the two drugs showed similar efficacy for reducing hot flash frequency and severity. However, elinzanetant showed a larger absolute reduction in hot flash frequency in some analyses, and its NK1 activity appears to provide a sleep benefit beyond what fezolinetant offers.

Neither drug has been directly compared head-to-head in a randomized controlled trial, so any comparison is indirect. What matters most is that you now have more choices. If one approach is not right for you, another may be. Use our treatment compare tool to explore how different therapies stack up for your specific symptoms. And if you are curious whether your symptoms even qualify as moderate to severe, our symptom quiz is a helpful starting point.

What About Cost and Access?

Lynkuet became available in US pharmacies in November 2025. The list price without insurance is approximately $625 per month. That is a significant out-of-pocket cost, but there are several pathways to make it more affordable:

Commercial insurance: Bayer has been actively working with insurance plans to add Lynkuet to formularies. With commercial insurance, eligible women may pay as little as $25 per month through Bayer's savings card program.

Uninsured or underinsured patients: Bayer's patient assistance program may provide the medication at no cost to women who qualify based on income and insurance status.

Telehealth access: You do not necessarily need to see a specialist in person to get a Lynkuet prescription. Many telehealth menopause providers are already prescribing it. If you live somewhere without easy access to a menopause-knowledgeable provider, a virtual visit may be your fastest path to a prescription.

To see menopause-experienced providers in your area who can evaluate whether Lynkuet or another treatment is right for you, browse our HRT provider directory. It can also be worth reading our guide to questions to ask your HRT doctor before your visit, so you walk in prepared.

Where Lynkuet Fits in the Bigger Picture

For years, the conversation about hot flash treatment was largely binary: hormone therapy or not. Hormone therapy remains the most effective option for vasomotor symptoms and is considered safe for most healthy women under 60 who are within 10 years of their last period, according to both The Menopause Society and current evidence-based guidelines. But "most" is not "all," and for those who are not candidates for hormones, or who simply prefer a different approach, the options were previously limited to behavioral strategies, SSRIs, and gabapentin, none of which were designed specifically for this purpose.

Elinzanetant changed that. It is the first drug ever developed with a mechanism targeting the precise brain pathway that causes hot flashes. The FDA's approval validates years of scientific work on KNDy neuron biology and gives providers a precise tool where before they had workarounds. The Menopause Society's 2025 Annual Meeting featured extensive data on the drug's real-world consistency across diverse patient populations, signaling that the medical community sees this as a meaningful addition to the treatment toolkit.

If you are also experiencing related symptoms like insomnia, mood swings, or anxiety, it is worth having a broader conversation with your provider. Hot flashes rarely travel alone, and a complete menopause treatment plan addresses the full picture. Our guide to starting treatment in perimenopause walks through how to think about that decision.

Elinzanetant will not be the right answer for every woman. But for those who need a non-hormonal, evidence-backed option that was purpose-built for menopausal hot flashes, Lynkuet represents something genuinely new: a drug born from a deep understanding of why hot flashes happen, designed to interrupt them at the source.

"For women who cannot use hormones or simply prefer not to, elinzanetant offers something the menopause field has needed for a long time: a treatment that was actually designed for this, from the ground up."

Medical Disclaimer: This article is for general educational purposes only and is not medical advice. Hormone therapy and menopause treatment decisions are individual and should be made with a qualified healthcare provider who knows your full history. Always consult your provider before starting or changing any treatment.